OURS is re-imagining and de-stigmatizing couples therapy. Photo by Mikhail Nilov/Pexels

A Houston startup that's re-imagining mental health treatment and counseling has emerged from stealth, announcing financial support from seed investors including tennis legend and venture capital investor Serena Williams.

Targeting the $5 trillion health and wellness market, OURS is founded by family therapist and author Liz Earnshaw, as well as Adam Putterman and Jessica Holton.

“We’re excited to take this first step in shifting the way we think about relationship health. We are building for a world that treats relationship health with equal importance as physical, mental and emotional health. We want working on your relationships to be an everyday experience, accessible to all,” says Holton, who serves as co-CEO, in a news release.

The company has raised nearly $5 million pre-seed and seed round from investors including TMV, Serena Ventures, Lakehouse Ventures, Collaborative Fund, GreyMatter, and pioneering angel investors such as Andy Dunn.

“Research shows that relationships are the most important factor to our overall health and wellbeing, which is an area that I'm hyper-focused on in my personal life,” says Williams, managing partner of San Francisco-based Serena Ventures, in the release. “When I learned about what the team was doing, I knew this was something we needed to support.

"OURS offers a reimagined and preventative solution to relationship wellness that's not only experiential and research-backed, but memorable and fun," she continues. "We're proud to be early investors in a brand that is making relationship health accessible to couples everywhere and play an integral part of the larger OURS mission.”

OURS has thousands of couples already using its platform. Image via OURS

The company launched its beta in 2020 and has already worked with thousands of customers and has an engaged community of couples across its platforms.

The OURS founders were inspired by their own experiences with couples counseling and created a technology-enabled platform based of expert and data-backed research.

“As it stands, the current mental health and wellness space is largely geared towards individuals, yet nearly 50 percent of couples have either participated in, or have sought out solutions, to foster stronger romantic partnerships,” says Soraya Darabi, co-founder and general partner at TMV, in the release. “However, a lack of therapists - until now - or confused perception of couples counseling leave needs unmet.”

Initially targeting romantic partners, the platform costs $400 for a four-week program that includes six personalized interactive sessions with an OURS guide at the helm of the experience. These one-hour technology-powered sessions are based around an innovative new technology, called Loveware, and include dynamic and meaningful conversations between a couple that are built around the magic that comes from being in the room with an expert.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."